<p><strong>Hims &amp; Hers Health Inc</strong> (NYSE:HIMS) shares are trading higher on Tuesday as investors continue to react to a new chief medical leadership appointment and lean into a generally constructive tape for healthcare stocks. Here’s what investors need to know.</p>



<ul>
<li>Hims &amp; Hers Health stock is surging to new heights today. What’s fueling HIMS momentum?</li>
</ul>



<h2>HIMS Stock: Key Levels And Momentum Indicators</h2>



<p>From a trend perspective, HIMS is acting like a &#34;repair&#34; rally: it's trading above its 20-day SMA ($25.39), 50-day SMA ($24.96), and 100-day SMA ($23.61), but it's still trading 17.8% below its 200-day SMA ($33.89), which keeps the longer-term bias cautious. That split often shows up when a stock is building a base but hasn't proven it can sustain a full trend reversal.</p>



<p>MACD is the cleaner momentum read right now: it's above its signal line and the histogram is positive, which suggests downside pressure is easing versus the prior downswing. In plain English, MACD compares faster and slower trend measures, and being above the signal line typically means momentum is improving rather than deteriorating.</p>



<p>The bigger-picture overhang is the death cross that set up in December 2025 (the 50-day SMA below the 200-day SMA), which is why bulls usually want to see follow-through that starts reclaiming longer-term averages. On the level-to-level map, $30.50 is the nearby area that can cap rebounds if buyers don't keep pressing.</p>



<ul>
<li><strong>Key Resistance</strong>: $30.50 — a nearby level where rebounds can stall, sitting just above current price and near the 200-day EMA zone ($30.55)</li>
</ul>



<h2>What Is Driving Hims &amp; Hers Health’s Stock?</h2>



<p>Hims &amp; Hers last week named <strong>Anant Vinjamoori</strong> as chief medical officer, pointing to his background in longevity medicine and preventive healthcare, and highlighting a medical leadership bench with more than 100 years of combined experience across weight loss, sexual health, hormone health, mental health, dermatology and primary care.</p>



<p>Vinjamoori framed the opportunity around demand for &#34;proactive, science-driven care,&#34; a message that fits Hims &amp; Hers' push to broaden beyond episodic treatment into longer-duration customer relationships.</p>



<h2>What Is Hims &amp; Hers Health?</h2>



<p>Hims &amp; Hers, launched in 2017, is a telehealth platform that connects patients and healthcare providers for areas like erectile dysfunction, hair loss, skin care, mental health and weight loss. It sells generic, branded, and compounded prescription drugs along with over-the-counter medicines, cosmetics and supplements.</p>



<p>The platform has more than 2 million subscribers and operates in all 50 states plus certain European markets like the UK, supported by provider networks, electronic medical records, cloud pharmacy fulfillment, and personalization tools. Because Hims doesn't take insurance and relies on direct customer payments, medical leadership and clinical credibility can matter for trust, retention, and expanding into proactive-care categories.</p>



<h2>HIMS Stock Price Movement On Tuesday</h2>



<p><strong>HIMS Stock Price Activity:</strong> Hims &amp; Hers Health shares were up 1.91% at $27.69 at the time of publication on Tuesday, according to Benzinga Pro data.</p>



<div class="bz-read-next-block">


<p>
<strong>
Read Also:

Stock Market Today: S&amp;P 500, Dow Jones Futures Gain Over Israel, Iran Ceasefire—Amplitech Group, Vail Resorts, Mission Produce In Focus
</strong>
</p>


</div>


<p><em>Image: Shutterstock</em></p>

HIMS

HIMY

HIMZ

<p>Hims & Hers Health (NYSE: HIMS) shares rose 1.91% to $27.69, driven by the appointment of Anant Vinjamoori as chief medical officer and positive sentiment in healthcare stocks. Technically, the stock shows improving momentum with MACD signals but remains below its 200-day SMA, facing resistance at $30.50.</p>

Hims & Hers Stock Edges Higher: What's Going On?